China Medical System H1 revenue rises on jump in sales of innovative and exclusive products

China Medical System Holdings

17/08/2026 14:37

Overview
China pharma group's H1 revenue rose 12.5% yr/yr to RMB4.5 bln
Net income attributable to shareholders up 4.8% to RMB986 mln for the period
Growth driven by innovative and exclusive products, which accounted for 37.7% of turnover

Outlook
Company did not provide specific financial guidance for the current quarter or full year in the press release

Result Drivers
INNOVATIVE PRODUCTS - Revenue from innovative and exclusive products rose 19.7% yr/yr and accounted for 37.7% of turnover
NEW DRUG APPROVALS - Three innovative drugs were approved for marketing in China during the period
PRODUCT PIPELINE - Multiple new drug applications and self-developed products received regulatory approvals, supporting future growth

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 4.50 bln
 
H1 Net Income Attributable
 
RMB 986.10 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for China Medical System Holdings Ltd is HK$17.50, about 48.7% above its August 17 closing price of HK$11.77
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 13 three months ago

Reuters Recommended Reads
Aug 17 - China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Aug 17 - Vaccine maker Sinovac H1 revenue rises on overseas growth, approvals
Aug 17 - Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)